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Abstract
A network of lineage-specific transcription factors and microRNAs tightly regulates differen-
tiation of hematopoietic stem cells along the distinct lineages. Deregulation of this regulatory
network contributes to impaired lineage fidelity and leukemogenesis. We found that the
hematopoietic master regulator RUNX1 controls the expression of certain microRNAs, of
importance during erythroid/megakaryocytic differentiation. In particular, we show that the
erythorid miR144/451 cluster is epigenetically repressed by RUNX1 during megakaryopoi-
esis. Furthermore, the leukemogenic RUNX1/ETO fusion protein transcriptionally represses
the miR144/451 pre-microRNA. Thus RUNX1/ETO contributes to increased expression of
miR451 target genes and interferes with normal gene expression during differentiation. Fur-
thermore, we observed that inhibition of RUNX1/ETO in Kasumi1 cells and in RUNX1/ETO
positive primary acute myeloid leukemia patient samples leads to up-regulation of miR144/
451. RUNX1 thus emerges as a key regulator of a microRNA network, driving differentiation
at the megakaryocytic/erythroid branching point. The network is disturbed by the leukemo-
genic RUNX1/ETO fusion product.
Author Summary
The regulatory network between transcription factors, epigenetic cofactors and micro-
RNAs is decisive for normal hematopoiesis. The transcription factor RUNX1 is important
for the establishment of a megakaryocytic gene expression program and the concomitant
repression of erythroid genes during megakaryocytic differentiation. Gene regulation by
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RUNX1 is frequently disturbed by mutations and chromosomal translocations, such as
the t(8;21) translocation, which gives rise to the leukemogenic RUNX1/ETO fusion pro-
tein. We found that RUNX1 regulates microRNAs, which are of importance at the mega-
karyocytic/erythroid branching point. Specifically, RUNX1 down-regulates expression of
the microRNA cluster miR144/451 during megakaryocytic differentiation by changing the
epigenetic histone modification pattern at the locus. We could show that miR451, one of
the micorRNAs of the miR144/451 cluster, supports erythroid differentiation. We found
that expression of miR451 is repressed by the RUNX1/ETO fusion protein, resulting in up
regulation of miR451 target genes. Our data support the notion that RUNX1 suppresses
the erythroid gene expression program including the erythroid microRNA miR451 and
that the RUNX1/ETO fusion protein interferes with normal gene regulation by RUNX1.
Introduction
The transcription factor RUNX1 (or AML1, acute myeloid leukemia 1) is a critical regulator of
embryonic and adult hematopoiesis (reviewed in [1–3]). Alteration in RUNX1 due to chromo-
somal translocations and mutations are causally connected to the onset of acute myeloid leuke-
mia in humans [4]. RUNX1 possesses a pivotal role in myeloid lineage differentiation, is a
crucial regulator of gene expression at the megakaryocytic/erythroid branching [5–7] and is
down-regulated during erythropoiesis [8,9]. We recently reported that RUNX1 inhibits ery-
throid differentiation by repressing the erythroid gene expression program [5]. During mega-
karyopoiesis sustained RUNX1 expression represses the erythroid master regulator KLF1 [5].
RUNX1 is involved in the t(8;21) chromosomal translocation found in approximately 15%
of acute myeloid leukemia cases, where the DNA binding runt homology domain (RHD) of
RUNX1 and almost the entire ETO (MTG8) protein are fused [10–12]. The resulting RUNX1/
ETO fusion protein can act as a constitutive transcriptional repressor, which occupies RUNX1
binding sites [13,14]. RUNX1/ETO does not induce leukemia on its own [15–17]. However, it
may contribute to outgrowth of a pre-leukemic clone, which by gathering additional mutations
evolves into leukemia [18]. A shorter variant of RUNX1/ETO, RUNX/ETO9a, lacking the C-
terminal domain of ETO induces leukemia in murine bone-marrow transplantation models
[19–21]. Similar to RUNX1, full length RUNX1/ETO has an inhibitory effect on erythropoiesis
[5,22]. Furthermore, both RUNX1 and its leukemic fusion protein RUNX1/ETO influence
expression of a number of microRNAs in normal differentiation and leukemia [23]. Thus, we
posit that the disturbance of lineage differentiation such as erythropoiesis by RUNX1/ETO
might be mediated through alterations of microRNA expression, in addition to the disturbance
of transcriptional networks [24]. Because RUNX1 inhibits erythroid gene expression [5] and
RUNX1/ETO interferes with erythroid differentiation [22], we were interested in downstream
microRNAs at the megakaryocytic/erythroid bifurcation.
The microRNAs miR144 and miR451 are up regulated during erythroid differentiation [25–
31]. MiR144 and miR451 are transcribed as one pri-microRNA (referred to as miR144/451),
which is regulated by the activity of the transcription factor GATA1 [26]. Interestingly, matu-
ration of miR144 and miR451 are distinct, as miR451 is processed dicer independently [32–
34]. Knock-down experiments have established a positive effect of mature miR451 on erythro-
poiesis [26,27,29,35,36] but little effect of mature miR144 [26,37].
In this study, we identified microRNAs downstream of RUNX1 in human hematopoietic
cells. We found that the erythroid specific miR144/451 cluster is transcriptionally regulated by
RUNX1 and TAL1, in addition to GATA1 [26]. We show that RUNX1 binds to the promoter
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of miR144/451 and is an epigenetic repressor of miR144/451 expression during megakaryo-
cytic differentiation. Thus RUNX1 contributes to the down-regulation of the erythroid gene
expression program by repressing miR451 transcription. Furthermore, the leukemogenic
RUNX1/ETO fusion protein interferes with miR144/451 expression and disturbs miR451 func-
tion. This RUNX1/ETO mediated repression of miR451 activity can be reversed by inhibition
of RUNX1/ETO.
Results
RUNX1 controls a network of hematopoietic microRNAs
We previously showed that RUNX1 represses the erythroid gene expression program during
megakaryocytic differentiation [5]. Thus we wanted to examine specifically which microRNAs
contribute to the biological function of RUNX1 at this differentiation point. To determine,
which microRNAs are regulated by RUNX1 at the megakaryocytic/erythroid branching we
used K562 erythroleukemia cells, as they have the potential to differentiate towards the ery-
throid or megakaryocytic lineage. We performed small-RNA sequencing upon over-expression
of RUNX1 in K562 cells (Fig 1A) and observed 588 altered small RNAs (Fig 1B and S1 File). Of
these altered small RNAs, 31 were snRNAs (small nuclear RNA), 45 rRNAs (ribosomal RNA),
142 snoRNAs (small nucleolar RNA) and 370 microRNAs (Fig 1B). A total of 237 microRNAs
were up-regulated and 133 microRNAs were down-regulated upon RUNX1 over-expression
(Fig 1C). Because RUNX1 is an important transcription factor for megakaryocytic and ery-
throid differentiation we were especially interested in microRNAs connected to RUNX1 with a
known role during erythroid or megakaryocytic differentiation (Fig 1D) [38,39]. Subsequently,
we analysed the relative expression of a subset of these microRNAs by q-RT-PCR detecting the
mature microRNAs in parental versus RUNX1 expressing cells (Fig 1E). All microRNAs mea-
sured by q-RT-PCR were regulated in the same direction as measured by RNAseq, except for
miR144 (S1 Fig). In line with published data miR27a, miR126, miR222, miR223 were sensitive
to changes in RUNX1 expression [40–44]. The expression of most differentially expressed
microRNAs was up-regulated, except miR126, miR144 and miR451. MiR144 and miR451 are
transcribed as one pri-microRNA, driven by a shared promoter. Because RUNX1 is a transcrip-
tional regulator we analysed expression of the transcriptionally regulated pri-micro RNA and
found that expression of the pri-microRNA (referred to as miR144/451) was decreased in
RUNX1 over-expressing K562 cells (Fig 1F and S2 Fig).
RUNX1 and TAL1 regulate miR144/451
To evaluate if RUNX1 directly influences miR144/451 expression, we analysed the 5’-region of
the miR144/451 locus in-silico, using the human genome browser [45]. Two regions in the 5’-
area of miR144/451 display a high degree of homology between species (Fig 2A and S3 Fig),
these areas are separated by a region of lower sequence homology (Fig 2A, not conserved or n.
c.). We identified potential RUNX1, TAL1 and GATA1 binding sites close to the transcrip-
tional start site and at an upstream (enhancer) region using TESS [46]. GATA1 binding at the
enhancer region had previously been demonstrated [26]. The enhancer and promoter regions
displayed high activity in a reporter gene assay in hematopoietic K562 cells compared to
embryonic kidney HEK293 cells (Fig 2B), indicating that the miR144/451 regulatory elements
are active in hematopoietic cells. By performing systematic over-expression and knock-down
experiments of RUNX1, TAL1 and GATA1 in K562 cells, we found that RUNX1 repressed
miR144/451 expression, while TAL1 and GATA1 activated it (S2 Fig).
Chromatin immunoprecipitation (ChIP) in primary hCD34+ and K562 cells revealed that
TAL1 mainly binds to the enhancer region of miR144/451 and to a less degree at the promoter
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Fig 1. Identification of RUNX1 regulated microRNAs. (A) Schematic representation of the experimental setup. K562 cells were transduced with RUNX1
expression vector or empty vector control. The transductions were performed in independent triplicates and differentially expressed microRNAs were
determined by small-RNA sequencing. (B) 588 small RNAs were differentially expressed upon RUNX1 expression in K562 cells. 31 were snRNAs (small
nuclear RNA), 45 rRNAs (ribosomal RNA), 142 snoRNAs (small nucleolar RNA) and 370 microRNAs. RNAs were included if they displayed an at least -0.5
or +0.5 log2-fold change and a P-value <0.05. (C)Of the 370 identified microRNAs, 237 were up-regulated and 133 down-regulated upon RUNX1
expression. (D) Schematic representation of hematopoiesis from the stem cell throughout the myeloid lineage. Those microRNAs are shown, which were
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region (Fig 2C and S4 Fig). In contrast, RUNX1 binding was mainly detected at the promoter
region of miR144/451 (Fig 2D). This promoter region harbours a RUNX1 binding site, which
is also present in the mouse promoter sequence (Fig 2E). We tested the influence of RUNX1 on
the miR144/451 promoter in a luciferase reporter assay and found that RUNX1 repressed
miR144/451 promoter activity (Fig 2F). Interestingly, the oncogenic RUNX1 t(8;21) fusion
proteins RUNX1/ETO (R/E) and also the truncated RUNX1/ETO (R/Etr) repressed miR144/
451 promoter activity (Fig 2F, wt prom). In contrast, neither RUNX1, nor R/E or R/Etr were
able to repress the promoter when the RUNX1 binding site was mutated (Fig 2F, RUNXmut
prom, compare Fig 2E). This indicates that both RUNX1 and its RUNX1/ETO leukemogenic
fusion protein repress the miR144/451 promoter by directly binding to the RUNX1 binding
site.
RUNX1 binding is associated with repression of miR144/451 expression
MiR144/451 expression is down-regulated during megakaryocytic and up-regulated during
erythroid differentiation of hCD34+ (Fig 3A) and K562 cells (S5 Fig). We found that RUNX1
binding at the promoter region of miR144/451 was reduced upon erythroid differentiation and
strongly up-regulated upon megakaryocytic differentiation of hCD34+ cells (Fig 3B) and K562
cells (S5 Fig). Concomitant to the enhanced RUNX1 binding to the miR144/451 promoter,
RUNX1 expression increased upon megakaryocytic differentiation at the protein level in CD34
cells (Fig 3C) and K562 cells (S5 Fig). Interestingly, upon megakaryocytic differentiation of pri-
mary hCD34+ cells an additional RUNX1 band appeared. These RUNX1 isoforms have been
described before as the RUNX1b (upper band) and RUNX1a (lower band) isoforms [47].
Increased RUNX1 binding at the promoter region during megakaryocytic differentiation was
accompanied by an increase of the RUNX1 associated corepressor protein PRMT6 [6,7] (Fig
3D). At the same time binding of the coactivators p300 and WDR5 decreased upon megakar-
yocytic differentiation in hCD34+ and K562 cells (Fig 3E and 3F). Concomitantly, the repres-
sive H3R2me2 histone modification mark increased, while the activating modification marks,
H3K9ac and H3K4me3, were significantly decreased in hCD34+ and K562 cells (Fig 3G, 3H
and 3I and S4 Fig). These data are in agreement with a repressive role of RUNX1 on erythroid
genes during megakaryocytic differentiation [5].
MiR451 influences erythroid differentiation of primary hCD34+ cells
A positive role of miR451 in erythropoiesis in cell lines, zebrafish and mouse models was dem-
onstrated [26,27,29,35]. This notion is also strengthened by our observation that the mature
miR451 is more abundant than mature miR144 upon erythroid differentiation (S6 Fig). To test
the influence of the single microRNAs in our differentiation system with primary hCD34
+ cells (S7 Fig), we constructed miR144/451 expression vectors (Fig 4A). These contained the
genomic region of the miR144/451 locus including the entire pri-microRNA (S8 Fig). The dif-
ferent constructs expressed either the wild type miR144/451 or versions, in which the seed
altered upon RUNX1 over-expression. The green arrow indicates a positive role and the red blunted arrow indicates a negative role in differentiation
according to published work. HSC: hematopoietic stem cell, MPP: multipotent progenitor, CMP: commonmyeloid progenitor, GMP: granulocyte monocyte
progenitor, MEP: megakaryocyte erythrocyte progenitor, MkP: megakaryocyte progenitor, EP: erythrocyte progenitor. (E) Independent evaluation of
microRNA expression. A subset of mature microRNAs influenced by RUNX1 and with a role in myeloid differentiation identified by RNA-sequencing, was
tested by q-RT-PCR. Q-RT-PCR values are given as relative expression of RUNX1 transduced K562 cells, compared to K562 cells transduced with empty
vector. Values were normalised to RNU6-2 expression. The error bars give the standard deviation from four independent determinations. All values were
significantly different from the control according to Student’s t test P <0.05. (F) RUNX1 over-expression leads to a decrease of miR144/451 (pri-microRNA)
transcript. Q-RT-PCR values are shown as fold expression compared to empty vector transduced K562 cells. Error bars represent the standard deviation
from four independent determinations. The P-value was calculated using Student’s t test. **P <0.01.
doi:10.1371/journal.pgen.1005946.g001
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Fig 2. Regulation of miR144/451 expression. (A) Schematic representation of the miR144/451 locus. The first 4700 bp of the 5’-region of miR144/451 are
shown. Binding sites for hematopoietic transcription factors are found about 4500 bp upstream (enhancer) and in the proximal promoter region (promoter). A
less conserved region (not conserved, n.c.) separates these regions. (B) Luciferase reporter gene experiment with constructs harbouring the enhancer or the
promoter region of the miR144/451 cluster. Reporter constructs were transfected into HEK293 cells or K562 cells, respectively. Relative light units (RLU) are
given as fold induction compared to values gathered with empty luciferase vector. Luciferase values were normalised for transfection variations by measuring
the activity of a cotransfected beta-galactosidase expression vector. Error bars indicate the standard deviation from six independent transfections and
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sequence of miR144 or miR451 was mutated, respectively (Fig 4B). We transduced human
CD34+ stem-/progenitor cells with the given constructs and performed colony-forming assays
(Fig 4C and S7 Fig). The total number of colonies was increased upon over-expression of
miR451 and reduced with miR144 compared to the empty vector control (Fig 4D). Expression
of the wild type miR144/451 construct did not alter erythroid colony formation, whereas
expression of the double mutant slightly reduced erythroid colony number. MiR451
(miR144mt/451) increased erythroid colony number, whereas miR144 (miR144/451mt)
increased CFU-G number, but had no effect on erythroid colonies (Fig 4E). In context of the
wild type miR144/451 construct miR144 seemed to counteract miR451 influence on erythopoi-
esis in this assay (Fig 4E). Taken together, our data confirm that miR451 positively influences
erythroid differentiation of primary hCD34+ progenitor cells.
RUNX1/ETO represses miR144/451 expression
The RUNX1/ETO (R/E) fusion protein and its truncated variant (RUNX1/ETO9a similar to R/
Etr) were shown to interfere with normal gene regulation by RUNX1 [49] and negatively
impact erythroid differentiation [22,50–52]. Furthermore, RUNX1/ETO repressed the
miR144/451 promoter in a reporter gene assay (compare Fig 2F). Thus, we wondered if some
of the RUNX1/ETO effects might be mediated through the modulation of endogenous
miR144/451. We found that RUNX1/ETO expression in primary hCD34+ cells reduced the
colony number in a CFU assay (Fig 5A). Of the remaining colonies, the frequency of erythroid
colonies was significantly reduced with the full-length RUNX1/ETO (R/E) and the truncated
form (R/Etr) (Fig 5B). Furthermore, RUNX1/ETO expression reduced expression of the ery-
throid marker GYPA (Fig 5C). Notably, RUNX1/ETO inhibited the expression of miR144/451
in primary hCD34+ cells (Fig 5D). Over-expression of RUNX1/ETO full length and RUNX1/
ETOtr in K562 cells (Fig 5E and 5F) left endogenous RUNX1 protein expression largely unaf-
fected and led to inhibition of miR144/451 expression (Fig 5G) similar to hCD34+ cells.
RUNX1/ETO also inhibited induction of miR144/451 expression under conditions that pro-
mote erythroid differentiation of K562 cells (Fig 5G). We then knocked-down R/Etr in K562
cells, which over-expressed R/Etr (Fig 5I and 5J) with an shRNA targeting the fusion site of
RUNX1/ETO [53,54]. This did not influence endogenous RUNX1 protein expression (Fig 5J).
In line with a repressive role of RUNX1/ETO, we observed increased miR144/451 expression
upon RUNX1/ETOtr knock-down (Fig 5K), showing that the effect of RUNX1/ETO on
miR144/451 expression is reversible. To determine if RUNX1/ETO binds endogenously to the
miR144/451 promoter, we performed a ChIP-assay in K562 cells expressing an HA-tagged
RUNX1/ETO and in Kasumi1 cells expressing endogenous RUNX1/ETO. In both cases, we
detected RUNX1/ETO at the miR144/451 promoter (Fig 5L and 5M). Expression of RUNX1/
ETOtr reduced the level of the activating histone mark H3K4me3 at the miR144/451 promoter
(Fig 5N) and led to decreased occupancy of RNApol-II in K562 cells (Fig 5O).
measurements. (C) ChIP assay in primary hCD34+ cells shows binding of TAL1 predominantly to the enhancer region (enh.) as opposed to the promoter
region (prom.). (D) ChIP assay in hCD34+ cells shows binding of RUNX1 to the promoter region (prom.) but only little to the enhancer region (enh.). (E) The
humanmiR144/451 promoter contains a conserved binding site for RUNX1. The RUNX1 binding site was mutated by changing two base pairs in the core
RUNX1 site. (F) Luciferase reporter assay using the wild type (wt prom) and the mutated (RUNXmut) miR144/451 promoters, respectively. Transfection of
RUNX1, the RUNX1/ETO (R/E) fusion protein or the truncated RUNX1/ETO (R/Etr) repressed wild type (wt prom), but not the mutated promoter (RUNX1mut
prom). Values are presented as fold change compared to the relative light units gathered upon transfection of the reporter gene and empty expression vector.
Luciferase values were normalised for transfection variations by measuring the activity of a cotransfected beta-galactosidase expression vector. Error bars
represent the standard deviation from six independent transfections and measurements. The P-value was calculated using Student’s t test. **P <0.01.
doi:10.1371/journal.pgen.1005946.g002
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Fig 3. MiR144/451 expression is epigenetically repressed duringmegakaryocytic differentiation. (A)MiR144/451 expression is decreased upon
megakaryocytic differentiation and increased upon erythroid expression of primary hCD34+ cells. Differentiation was done for 6 days (see S7 Fig).
Expression of the endogenous pri-microRNA was measured by q-RT-PCR. (B) ChIP assay analysis of RUNX1 binding to the miR144/451 promoter during
erythroid (CD34-E) or megakaryocytic (CD34-M) differentiation of hCD34+ (CD34) cells. (C) Analysis of RUNX1 protein abundance in hCD34+ cells and
upon megakaryocytic differentiation (CD34-M) byWestern blot using a RUNX1 antibody and a lamin antibody as loading control. (D-I)Cofactor and histone
modification changes at the promoter of miR144/451 during megakaryocytic differentiation (CD34-M) using ChIP analysis in hCD34+ cells. (D-F)ChIP
analysis reveals altered binding of PRMT6, p300 andWDR5 to the miR144/451 promoter upon megakaryocytic differentiation. (G-I) ChIP reveals altered
H3R2me2, H3K9ac and H3K4me3 at the miR144/451 promoter upon megakaryocytic differentiation. (D-I)Q-PCR values are given as percent input. Histone
modification ChIP values were corrected by a Histone 3 ChIP for nucleosome density. The error bars represent the standard deviation from at least four
independent determinations. The P-values were calculated using Student’s t test. **P <0.01, ***P <0.001.
doi:10.1371/journal.pgen.1005946.g003
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Fig 4. MiR451 increases erythroid differentiation. (A) Schematic representation of miR144/451 expression constructs. The genomic sequence of human
miR144/451 was cloned into the LEGO vector [48] behind the GFP expression cassette, which is driven by a spleen focus-forming virus promoter. The wild
type and mutant constructs are shown, with the X marking the mutational site. (B) The mutations introduced in the seed sequences of miR144 and miR451
are indicated. (C) A colony formation assay was performed with sorted GFP-positive transduced hCD34+ cells. (D) The total number of colonies in the colony
formation assay is shown. Colonies were counted on day 12. E) The frequency (%) of erythroid colonies among total colonies in the colony formation assay is
shown. Error bars represent the standard deviation of four independent determinations. *P-value <0.05, ***P-value <0.001 according to Student’s t test.
doi:10.1371/journal.pgen.1005946.g004
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Fig 5. RUNX1/ETO inhibits miR144/451 expression during erythroid differentiation. (A) Colony formation assay with sorted GFP-positive transduced
hCD34+ cells shows that full-length RUNX1/ETO (R/E) and RUNX1/ETOtr (R/Etr) inhibit colony formation. The average number of colonies per experiment is
given. The error bars give the standard deviation from four independent experiments. (B) The percentage of erythroid colonies is reduced in a colony
formation assay upon transduction of hCD34+ cells with R/E or R/Etr. Shown is the relative abundance of erythroid colonies in percent. (C) Expression of the
erythroid marker gene GYPA is reduced on the mRNA level upon transduction of hCD34+ cell with R/E or R/Etr, as measured by q-RT-PCR. (D) Expression
of the pri-miR144/451 is reduced upon transduction of hCD34+ cells with R/E or R/Etr, as shown by q-RT-PCR. (E) Expression of full length RUNX1/ETO (R/
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MiR144/451 expression can be reactivated by inhibition of RUNX1/ETO
Because RUNX1/ETO influences miR144/451 expression in transduced K562 and hCD34
+ cells, we analysed miR144/451 expression in two RUNX1/ETO dependent cell lines
(Kasumi1, SKNO1) and RUNX1/ETO positive primary AML samples (Fig 6A and 6B).
RUNX1/ETO expression of Kasumi1, which is an established RUNX1/ETO model cell line,
was set as one. We measured 5-fold higher RUNX1/ETO expression in SKNO1 cells, the
patient samples #1 expressed 3-times less RUNX1/ETO than Kasumi1 cells and patient sample
#2 expressed the highest R/E mRNA level (Fig 6A). Human primary CD34+ and HEK293 cells
expressed no RUNX1/ETO (Fig 6A). Subsequently, we determined miR144/451 expression lev-
els. Compared to normal hCD34+ cells, RUNX1/ETO expressing samples exhibited lower lev-
els of miR144/451 (Fig 6B). To determine if endogenous RUNX1/ETO contributes to the
repression of miR144/451 we knocked-down RUNX1/ETO in Kasumi1 cells as described (Fig
6C) [53]. This indeed led to increased expression of miR144/451 (Fig 6C). As it was demon-
strated that the HDAC inhibitor trichostatin-A (TSA) leads to degradation of RUNX1/ETO
[55], we treated Kasumi1 cells (Fig 6D) with TSA. We found that treatment of Kasumi1 cells
with 0.01 uM TSA lead to degradation of RUNX1/ETO and the appearance of a degradation
band, at higher TSA levels the RUNX1/ETO protein entirely disappeared (Fig 6D). When we
measured miR144/451 levels in TSA treated Kasumi1 cells, we found that miR144/451 levels
increased upon treatment (Fig 6E). Similarly, treatment of the primary RUNX1/ETO positive
patient samples with TSA led to increase of miR144/451 expression (Fig 6F). These data
strengthen the notion of a link between RUNX1/ETO and miR144/451 expression, which is
sensitive to pharmacological inhibition of RUNX1/ETO.
RUNX1/ETO and miR451 target gene expression is connected
Our results suggest a connection between RUNX1/ETO expression and disturbed erythroid dif-
ferentiation. As we found that mostly miR451 (and not miR144) acts on erythropoiesis (Fig 4),
we were interested if RUNX1/ETO would influence the expression of miR451 targets. We over-
expressed miR451 in K562 cells (Fig 7A) and analysed the expression of the known miR451 tar-
gets UBE2H, 14-3-3 and IL6R [25,27,56,57]. As microRNAs can act on mRNA stability and
translation we examined the mRNA level (Fig 7) and the protein amount (S9 Fig). UBE2H, 14-
3-3ξ and IL6R mRNA was decreased upon miR451 over-expression (Fig 7B–7D). Furthermore,
we detected a reduction of UBE2H and 14-3-3ξ at the protein level, whereas IL6R remained
unchanged (S9 Fig). In contrast, RUNX1/ETO increased UBE2H and 14-3-3ξmRNA expres-
sion (Fig 7E and 7F), however RUNX1/ETO did not influence IL6R significantly (Fig 7G).
E) in transduced K562 cells. Western blot was performed with anti-HA-antibody, which detects the transduced R/E. Endogenous RUNX1 was detected with
anti-RUNX1 antibody. Tubulin served as a loading control. (F) Expression of truncated RUNX1/ETO (R/Etr) in transduced K562 cells. Western blot was
performed with anti-HA-antibody, which detects the transduced R/E. The endogenous RUNX1 was detected with an anti-RUNX1 antibody. Tubulin served as
a loading control. (G) Expression of pri-miR144/451 is reduced upon transduction of K562 cells with R/E or R/Etr as measured by q-RT-PCR. (H) Induction of
the miR144/451 cluster during erythroid differentiation is impaired upon transduction of K562 cells with R/E or R/Etr. Transduced K562 cells were treated with
30 μM hemin. (I-J) Knock-down of R/Etr expression in R/Etr-K562 cells with an shRNA targeting R/E. (I) The knock-down of R/Etr is shown on the mRNA
level by q-RT-PCR. (J) The knock-down of R/Etr is shown on the protein level by Western blot using an HA-tag antibody, which detects the transduced R/Etr.
An antibody against RUNX1 detected the endogenous RUNX1. Tubulin served as a loading control. (K) Knock-down of R/E by shRNA increases miR144/
451 expression measured by q-RT-PCR. (C-K) Expression data were gathered by q-RT-PCR with gene specific primer pairs, values were normalised to
GAPDH expression. Shown is the relative expression compared to cells transduced with empty vector or expression vectors harbouring a no-targeting
shRNA, respectively. Error bars represent the standard deviation from at least four determinations. (L) ChIP assay in K562 cells transduced with HA-tagged
RUNX1/ETO (R/E-HA) shows binding of R/E-HA to the miR144/451 promoter. For ChIP an anti-HA-tag antibody was used. (M) ChIP assay in Kasumi1 cells
provides evidence that endogenous RUNX1/ETO binds to the miR144/451 promoter. For ChIP an anti-ETO antibody was used. (N) ChIP assay with K562
cells transduced with R/Etr using an anti-H3K4me3 antibody reveals reduced H3K4 methylation. (O) ChIP assay with K562 cells transduced with R/Etr using
an anti-RNApol-II antibody reveals reduced RNA polymerase II occupancy. (L-O)Q-PCR was performed with primers in the promoter region of miR144/451.
The P- values were calculated using Student’s t test. **P <0.01, ***P <0.001.
doi:10.1371/journal.pgen.1005946.g005
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Taken together, we detected an effect of miR451 on reported target mRNAs and could also
show that RUNX1/ETO influences expression of the miR451 targets UBE2H and 14-3-3ξ. Thus,
we propose that RUNX1/ETO represses expression of the miR144/451 cluster, which leads to
up-regulation of miR451 targets, contributing to altered differentiation (Fig 7H).
Discussion
Our study shows that RUNX1 influences the expression of specific microRNAs involved in
megakaryocytic/erythroid differentiation. Interestingly, RUNX1 acts as an activator of some
Fig 6. Inhibition of RUNX1/ETO increasesmiR144/451 expression. (A) Expression of endogenous RUNX1/ETO in Kasumi1, SKNO1 and two RUNX/
ETO positive patient samples. Expression of RUNX1/ETO in Kasumi1 cells was set as 1 and the expression levels of the SKNO1 cells and two patient
samples are shown as fold compared to Kasumi1 cells. HEK293 and hCD34+ serve as RUNX1/ETO negative controls. Values were gathered by q-RT-PCR
and normalised to GAPDH. (B) Expression of miR144/451 in Kasumi1, SKNO1 and two different patient samples. HEK293 and hCD34+ served as miR144/
451 negative and positive controls, respectively. Q-RT-PCR values were normalised to GAPDH expression and are shown as fold relative to values gathered
with Kasumi1 cells. (C) Knock-down of RUNX1/ETO in Kasumi1 cells. Knock-down of RUNX1/ETO by an shRNA targeting the R/E fusion site leads to
increased miR144/451 expression. (D) Treatment of Kasumi1 cells with trichostatin-A (TSA) leads to degradation of RUNX1/ETO. Kasumi1 cells were
treated with the indicated concentrations of TSA for 24 hours. Protein expression was determined byWestern blot using an anti-ETO antibody. R/E runs at
about 100 kD. As loading control (l.c.) a protein band running at 55 kD visible upon Ponceau S staining of the membrane is shown. (E)MiR144/451
expression is up-regulated in Kasumi1 cells upon TSA treatment. MiR144/451 expression upon treatment with TSA was measured by q-RT-PCR. Values
were normalised to GAPDH expression. (F)MiR144/451 expression is up-regulated in patient samples upon TSA treatment. Cells were treated with 1 uM
TSA for 24 hours. Q-RT-PCR values were normalised to GAPDH expression. Q-RT-PCR against RUNX/ETO was performed with specific primers detecting
the fusion protein. Error bars give the standard deviation from at least four independent determinations. The P-values were calculated using Student’s t test.
**P <0.01, ***P <0.001.
doi:10.1371/journal.pgen.1005946.g006
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Fig 7. MiR451 and RUNX1/ETO influencemiR451 target genes. (A) Schematic overview of K562
transduction with a miR451 expression vector, sorting and treatment. K562 cells were transduced, cultured
for 6 days and sorted according to the GFP signal. GFP-positive cells were further analysed. (B)MiR451
over-expression in K562 cells leads to down-regulation of the miR451 target UBE2H at the mRNA level. (C)
MiR451 over-expression in K562 cells leads to down-regulation of the miR451 target 14-3-3ξ at the mRNA
level. (D)MiR451 over-expression in K562 cells leads to down-regulation of the miR451 target IL6R at the
mRNA level. (E)Over-expression of RUNX1/ETO increases UBE2H expression at the mRNA level. (F)Over-
expression of RUNX1/ETO increases 14-3-3ξ expression at the mRNA level. (G)Over-expression of RUNX1/
ETO has only a minor influence on IL6RmRNA expression. (B-G)Q-RT-PCR values are shown as relative
expression compared to K562 cells transduced with an empty control vector and normalised to GAPDH
expression. The error bars represent the standard deviation from at least four independent determinations.
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microRNAs, which suppress erythropoiesis. Thus inversely, the down-regulation of RUNX1
during erythropoiesis would diminish expression of these microRNAs and further support
erythropoiesis. For example the microRNAs miR221 and miR222 are negatively influencing
erythropoiesis through targeting the c-kit receptor and are both down-regulated during ery-
throid differentiation [58]. Similarly, down-regulation of miR223 enhances erythropoiesis
through de-repressed expression of its target LMO2 [59]. MiR221/222 and miR223 are directly
repressed by RUNX1/ETO [42,43], which provides a good example of the intricate relationship
between RUNX1, RUNX1/ETO and microRNAs in normal differentiation and leukemia.
Another group of microRNAs, which we found up-regulated by RUNX1 are known to posi-
tively influence megakaryopoiesis, such as miR34a, miR146 and miR150 [60–65]. Furthermore,
we could reproduce the previously described up-regulation of miR27a by RUNX1, which was
itself shown to target RUNX1, thereby implementing a feed back regulatory loop [40]. Our
study also revealed that RUNX1 represses the expression of two microRNAs namely miR126
and the microRNAs of the miR144/451 cluster. MiR126 inhibits erythropoiesis from embry-
onic stem cells, partly by targeting the protein tyrosine phosphatase, nonreceptor type 9
(PTPN9) [66]. Interestingly, alteration of miR126 expression promotes leukemogenesis in
cooperation with RUNX1/ETO [67]. Our observation that RUNX1 influences miR126 suggests
a relationship between RUNX1 and RUNX1/ETO in the regulation of miR126. However, it is
not known if miR126 is directly influenced by RUNX1 or RUNX1/ETO. Recently, miR126 was
demonstrated to regulate self-renewal and quiescence of normal hematopoietic stem cells
(HSC) and acute myeloid leukemia stem cells (LSC) [68,69]. In the same landmark paper the
authors found that miR451 expression is high in the non-LSC population [68]. Whether the
lower amount of miR451 in LSCs compared to HSCs is functionally significant currently
remains elusive.
Because of its role in erythropoiesis we focused on miR144/451 [26,27,29,35], as we recently
reported that RUNX1 epigenetically represses the key erythroid transcription factor KLF1 [5].
In line with the notion that RUNX1 inhibits the erythroid gene expression program during
megakaryopoiesis, our data reveal that RUNX1 is a repressor of the erythroid miR144/451
microRNA cluster. We found that RUNX1 and TAL1 are bound to miR144/451 regulatory
sequences in undifferentiated hCD34+ cells, which allows some degree of expression. However,
upon megakaryocytic differentiation RUNX1 binding is increased, concomitantly RUNX1
associated corepressors such as PRMT6 (protein arginine methyltransferase 6) [6,7] are
recruited. These trigger repressive histone modification marks and miR144/451 is down-regu-
lated. Repression of miR144/451 expression by RUNX1 is in line with the observation that
expression of miR144/451 increases during erythroid differentiation, when RUNX1 expression
is down-regulated [8,9]. In contrast miR144/451 expression is positively regulated by the tran-
scription factors TAL1 and GATA1. Both transcription factors have been shown to be impor-
tant activator of the erythroid gene expression program [70–74]. Taken together our data
confirm that miR144/451 is an erythroid microRNA [26,35,37], which is activated by TAL1/
GATA1 but repressed by RUNX1 during megakaryopoiesis.
RUNX1 has been mainly described as a transcriptional activator, however it can also act as a
transcriptional repressor [5,6,75–79]. In contrast, RUNX1/ETO mostly acts as a transcriptional
repressor, which recruits a corepressor complex including N-CoR and Sin3 [11,13,49] although
The P-values were calculated using Student’s t test. **P< 0.01, ***P< 0.001. (H) Schematic representation
of RUNX1/ETO activity on miR451 target genes. RUNX1/ETO represses transcription of the miR144/451 pri-
microRNA, leading to less miR451 in the cells. As a consequence miR451 targets are up-regulated, which
contributes to altered differentiation.
doi:10.1371/journal.pgen.1005946.g007
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in some cases RUNX1/ETO also activates genes [80]. Because RUNX1 and RUNX1/ETO are
simultaneously expressed in leukemic cells it is an interesting question how they interact on
miR144/451 expression. Genome wide studies have shown that RUNX1/ETO and RUNX1
compete for binding to the same binding sites [24] and it has been suggested that RUNX1/ETO
serves as a dominant negative inhibitor of RUNX1 function [49]. However recent data imply
that RUNX1/ETO does not act exclusively as a dominant negative repressor of RUNX1 func-
tion [80]. Knock-down of RUNX1/ETO leads to genome wide changes of the chromatin struc-
ture and to novel RUNX1 binding sites at places where no RUNX1/ETO was bound before
[81]. Furthermore, cell lines expressing RUNX1/ETO, such as Kasumi1, grow dependent on
the presence of wild type RUNX1 [82]. At the molecular level there is evidence of a dynamic
balance of RUNX1 and RUNX1/ETO activity in leukemia cells [24]. Our data show that
RUNX1 and RUNX1/ETO not exclusively compete functionally, as both can act as repressor
on the miR144/451 promoter. This confirms that both can have a similar function on a target
gene. Our data imply that both RUNX1 and RUNX1/ETO inhibit the erythroid gene expres-
sion program ([5], this study). However, RUNX1 represses erythroid gene expression upon
megakaryocytic differentiation, upon up-regulation of RUNX1 [5]. In contrast, the t(8;21)
takes place in an early stem cell or progenitor stage and can even be detected in healthy new-
born children [83]. Accordingly, differentiation of RUNX1/ETO cells is blocked at an early
myeloid stage and about 40% of the immature M2-type of leukemia are RUNX1/ETO depen-
dent [10]. Our data imply that RUNX1/ETO would repress expression of miR144/451 similar
to RUNX1. But RUNX1/ETO would repress miR144/451 at an inappropriate differentiation
stage and thus interfere with normal differentiation contributing to impaired lineage fidelity of
RUNX1/ETO expressing cells.
In line with this notion the RUNX1/ETO fusion protein was found to repress erythroid dif-
ferentiation [22,50–52]. This effect was dependent on the presence of the NHR4 domain within
the C-terminal domain of the fusion protein [22]. However, the inhibitory effect of RUNX1/
ETO was not consistent in all studies [84] and the effect of the RUNX1/ETO truncated form
(REtr or RE9a) was not tested. Our results show that full length RUNX1/ETO and the trun-
cated RUNX1/ETOtr equally decreased erythroid differentiation of primary hCD34+ cells.
Notably, the repression of miR144/451 by RUNX1/ETO was released by knock-down of
RUNX1/ETO in Kasumi1 cells. Furthermore, treatment of primary AML patient samples with
TSA, which leads to degradation of RUNX1/ETO [55], increases miR144/451 expression.
Additionally, we showed that RUNX1/ETO expression leads to an up-regulation of the
miR451 targets UBE2H and 14-3-3ξ. Notably, the connection of miR451 with 14-3-3ξ expres-
sion has been linked to erythroid differentiation [27]. This supports the idea that RUNX1/ETO
represses miR451 expression thereby inducing the expression of miR451 target mRNAs.
Our results and data gathered by others [23,43] suggest that RUNX1 acts as master regulator
of a regulatory microRNA network in hematopoietic differentiation, which is disturbed by the
leukemogenic RUNX1/ETO fusion product.
Material and Methods
Cell culture
K562, Kasumi1, SKNO1 and HEK293T/17 (ATCC CRL-11268) cells were cultured in Roswell
Park Memorial Institute 1640 medium (RPMI; Life Technologies) and Dulbecco’s modified
eagle medium (DMEM; Life Technologies), respectively. Supplements were 10% fetal calf
serum (FCS), 2 mM glutamine and 1% penicillin/streptomycin. Kasumi1 cells were supple-
mented with 20% FCS. SKNO1 cells were supplemented with 10 ng/mL granulocyte-macro-
phage colony stimulation factor (GM-CSF). K562 cells were treated with 30 nM 12-o-
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tetradecanylphorbol-13-acetate to induce megakaryocytic differentiation. For erythroid differ-
entiation K562 cells were incubated with 30 μM hemin. For TSA treatment three concentra-
tions of trichostatin-A (TSA) (Sigma Aldrich), 0.01 μM, 0.5 μM and 1.0 μMwere used. Cell
density was set to 0,5x106 cells/ml incubation with TSA was for 24 hours. Gene expression was
analysed by quantitative real-time PCR. Primary AML-patient samples were gathered with
written informed consent. G-CSF mobilized human primary CD34+ cells were from healthy
volunteer donors with written informed consent. The local ethics committee approved the
experiments (permit #329–10).
Primary human CD34+ cell culture
hCD34+ cell were isolated from G-CSF mobilized peripheral blood using immunomagnetic
selection according to the manufacturer’s instructions (Miltenyi Biotec, Bergisch Gladbach,
Germany). Thereafter, the hCD34+ cells were expanded for 3 days in serum-free expansion
medium (StemSpan SFEM, Stemcell Technologies, Grenoble, France) supplemented with 100
ng/ml FLT-3, 100 ng/ml SCF, 20 ng/ml IL-3 and 20 ng/ml IL-6 (Miltenyi Biotec). hCD34
+ cells were transduced with lentiviral vectors expressing also green fluorescent protein (GFP),
which enabled sorting the cells according to their GFP signal (FACSAria, BD-Biosciences,
Heidelberg).
Transductions were performed with an MOI of 25. Knock-down constructs for shRUNX1/
ETO were designed using the SEW-backbone as described [85,86]. The SiEW or the LEGO len-
tiviral vector was used for over-expression [48]. Transduced hCD34+ cells were either seeded
out on methylcellulose plates for CFU assay according to the manufacturer’s instructions
(StemMACS HSC-CFU with Epo, Miltenyi Biotec). Colonies were counted on day 12 after
seeding. To induce erythroid differentiation the expanded hCD34+ cells were cultured in Stem-
Span serum-free expansion medium II (SFEM II, Stemcell Technologies) supplemented 20 ng/
ml SCF, 5 ng/ml IL-3, 2 μM dexamethasone (Sigma-Aldrich, Munich, Germany), 0,2 μM estra-
diol (Sigma-Aldrich) and 1U/ml erythropoietin (PeproTech, Hamburg, Germany) [87]. For
megakaryocytic differentiation hCD34+ cells were incubated with SFEM II supplemented with
megakaryocyte expansion cytokine cocktail (StemSpan Megakaryocyte Expansion Supplement,
Stemcell Technologies). Differentiation was verified by RT-PCR for differentiation markers
[5,6] and by FACS (S7 Fig). ChIP experiments were performed with hCD34+ differentiated
cells (upon 6 days) and compared to hCD34+ cells cultured in expansion medium for the same
time. Experiments were performed with hCD34+ cells from at least two independent donors.
Chromatin immunoprecipitation
Preparation of cell lysates for chromatin immunoprecipitation (ChIP) assays was performed
according to the X-ChIP protocol (Abcam) with modifications [5]. 2.5–10 μg of antibodies
were used for immunoprecipitation. ChIP-DNA was purified using DNA purification columns
(ChIP DNA Clean and Concentrator, Zymo Research, USA) and eluted with 40 μl TE-buffer.
DNA was analyzed by quantitative PCR. Antibodies and ChIP-PCR primers are given in S2
File. DNA recovery was calculated as percent of the input, bars represent the standard devia-
tion from at least four independent determinations. ChIP-values of histone modification were
corrected for nucleosome density using values gathered by a Histone 3 ChIP.
Luciferase assay
The human miR144/451 promoter region (-750 bp) was cloned into the pGL4.10 vector. The
enhancer region (3410–4680 bp) of miR144/451 was cloned in front of a minimal promoter
into the pGL4.23 vector. K562 and HEK293T cells were transfected with Metafectene (Biontex,
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Martinsried/Planegg, Germany) with the reporter plasmids and a β-galactosidase expressing
vector. 48 h after transfection the luciferase and β-galactosidase activity was analyzed. To con-
trol for transfection efficiency the firefly luciferase activity was normalized to β-galactosidase.
RNA isolation and quantitative RT-PCR
For RNA isolation the miRNeasy Mini Kit (Qiagen, Valencia, CA, USA) was used to purify a
miRNA-enriched fraction and a total RNA fraction separately. cDNA was synthesized from
the total RNA fraction using Omniscript reverse transcriptase kit (Qiagen). Quantitative
RT-PCR was performed using a LightCycler 480 (Roche, Mannheim, Germany) and SYBR--
Green PCRMasterMix (Eurogentec, Köln, Germany). Relative amounts of mRNA were calcu-
lated by the ΔΔCt method using GAPDH or TBP as controls. To detect and quantify mature
miRNAs a Taqman assay (Life Technologies) or the miScript SYBR Green PCR Kit (Qiagen)
was used. Primer pairs, Taqman probes and primer assays are given in supplementary
material.
Small RNA sequencing
Total RNA was isolated from K562 cells using the Trizol (Invitrogen) method according to the
manufacturer's recommendations. Afterwards, the samples were DNAse I (Sigma) treated in
order to remove DNA contamination. RNA quality was determined using the Agilent 2100
Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA) microfluidic electrophoresis. Only
samples with comparable RNA integrity numbers were selected for deep sequencing. Library
preparation for small RNA-Seq was performed using the TruSeq Small RNA Sample Prepara-
tion Kit from Illumina (catalog RS-200-0012) starting from 1000 ng of total RNA. Accurate
quantitation of cDNA libraries was performed using the QuantiFluorTM dsDNA System (Pro-
mega). The size range of cDNA libraries was determined applying the DNA 1000 chip on the
Bioanalyzer 2100 from Agilent (140–160 bp). cDNA libraries were amplified and sequenced by
using the cBot and HiSeq2000 from Illumina (SR, 1x51 bp, 4 GB per sample). Sequence images
were transformed with Illumina software BaseCaller to bcl files, which were demultiplexed to
fastq files with CASAVA (version 1.8.2). Quality check was done via FastQC (version 0.10.1,
Babraham Bioinformatics). Differentially expressed small RNA molecules were identified
using the OASIS platform with standard parameters. RNAs were included for further analysis
if they displayed an at least -0.5 or +0.5 log2-fold change and a P-value<0.05. Sequencing data
are available at the GEO-database under the accession number GSE70942.
Supporting Information
S1 Fig. Expression changes of microRNAs upon RUNX1 over expression, involved at the
MEP branching. The log2 fold changes according to the sequencing date are shown and the
fold changes according to q-RT-PCR detecting the mature microRNAs (values as in Fig 1E).
(TIF)
S2 Fig. Regulation of miR144/451 expression. (A-C) MiR144/451 is regulated by RUNX1.
(A) RUNX1 over-expression leads to a decrease of miR144/451 transcript in K562 cells (same
graph as in Fig 1F). (B) RUNX1 knock-down increases miR144/451 amount in K562 cells. (C)
Western blot showing RUNX1 over-expression and RUNX1 knock-down, respectively. (D-F)
MiR144/451 expression is regulated by TAL1. (D) TAL1 over-expression slightly increases
miR144/451 expression in K562 cells. (E) Knock-down of TAL1 decreases miR144/451 expres-
sion in K562 cells. (F) Western blot showing TAL1 over-expression and TAL1 knock-down in
K562 cells, respectively. (G-I) GATA1 regulates miR144/451 expression. (G) GATA1 over-
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expression increases miR144/451 expression in K562 cells. (H) GATA1 knock-down decreases
miR144/451 expression in K562 cells. (I) Western blot showing GATA1 over-expression and
GATA1 knock-down in K562 cells, respectively. Q-RT-PCR was performed with specific prim-
ers for the given mRNAs. Error bars give the standard deviation of at least four independent
determinations. P-values were calculated by Student’s t test. P<0.05, P<0.01, P<0.001.
(TIF)
S3 Fig. Genomic region 5‘ of the miR144/451 cluster. Screenshot from the human genome
browser: Shown is the genomic region of miR144/451. The coding regions of miR144 and
miR451 are marked by red boxes. These regions display a high degree of conservation. Two
regions 5‘ of the coding region display a higher degree of conservation and are marked with a
green bar (Enhancer Region) and a blue bar (Promoter Region). These regions have heightened
H3K27Ac marks, which is indicative of regulatory regions (blue). In addition the enhancer
region and the promoter region have a high density of transcription factor binding, which is
indicated by the black bar within the figure (Txn Factor ChIP).
(TIF)
S4 Fig. (A) ChIP analysis shows binding of TAL1 to the enhancer and promoter regions of
miR144/451 in K562 cells. (B-F) ChIP analysis shows alterations at the miR144/451 promoter
upon megakaryocytic differentiation of K562 cells (K562-M). (B) Binding of TAL1 to the pro-
moter region of miR144/451 before and after megakaryocytic differentiation. (C-D) H3R2me
and the corresponding PRMT6 at the promoter region of miR144/451 before and after mega-
karyocytic differentiation. (F-G) WDR5 and the corresponding H3K4me3 at the miR144/451
promoter before and after megakaryocytic differentiation. Q-PCR was performed with primers
binding in the promoter region of miR144/451. Values are given as percent input. Histone
modification ChIPs were normalised to values gathered with an anti Histone3 ChIP. Error bars
represent the deviation from at least four independent experiments. P-values were calculated
according to Student’s test. P<0.01, P<0.001.
(TIF)
S5 Fig. (A) MiR144/451 expression is decreased upon megakaryocytic differentiation and
increased upon erythroid expression of K562 cells. Expression of the endogenous pri-micro-
RNA was measured by q-RT-PCR. (B) Analysis of RUNX1 protein abundance in K562 cells
and upon megakaryocytic differentiation (K562-M) by Western blot using anti-RUNX1 anti-
body and anti-Lamin antibody as control. (C) ChIP assay analysis of RUNX1 binding to the
miR144/451 promoter during erythroid (K562-E) or megakaryocytic (K562-M) differentiation
of K562 cells.
(TIF)
S6 Fig. The mature microRNAs miR144 and miR451 increase upon erythroid differentia-
tion to a different degree. hCD34+ cell were differentiated towards the erythroid linage for 6
days. The mature micro RNAs were determined by q-RT-PCR values were normalised to
RNU6-2 expression and are shown as fold over values gathered for undifferentiated hCD34
+ cells. Error bars give the standard deviation of at least four independent determinations. P-
values were calculated using Student’s t test. P< 0.05. P< 0.01.
(TIF)
S7 Fig. (A) Scheme of hCD34+ CFU assay upon transduction. Upon isolation hCD34+ cells
were expanded for 3 days and transduced. After two days the cells were sorted and GFP posi-
tive cells were seeded in 3.5 cm dishes. (B) Erythroid differentiation of hCD34+ cells. Cells
were expanded for 3 days and subjected to erythroid differentiation. The cells erythroid cell
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surface marker GYPA and CD71 increase as shown by FACS. (C) Megakaryocytic differentia-
tion of hCD34+ cells. Cells were expanded for 3 days and megakaryocytic differentiation was
induced. Shown is the increase of the megakaryocytic surface marker CD61 as measured by
FACS.
(TIF)
S8 Fig. (A) Screen shot of the genomic region of miR144/451 (altered). The miR144 and
miR451 coding regions are highly conserved. The genomic region, which was cloned into a len-
tiviral expression vector (compare Fig 4) is marked. (B) Expression validation of the miR144/
451 constructK562 cells were transfected with the miR144/451 pri-microRNA expression vec-
tor. Expression of the mature microRNAs miR144 and miR451 was determined using Taq-
man q-RT-PCR. (C) The cloned miR144/451 genomic region is given. The miR144 region is
marked in bold, the miR451 region is marked in red. The micro-RNA coding regions, which
were mutated are underlined (compare Fig 4). The grey areas are the primer regions used for
cloning.
(TIF)
S9 Fig. Influence of miR451 over-expression on its targets UBE2H, 14-3-3z and IL6R. The
effect of miR451 over-expression on protein levels was determined in K562 cells. Western blot
was performed using specific antibodies against the given proteins. Tubulin was used as load-
ing control.
(TIF)
S1 File. Supplementary data file.
(XLSX)
S2 File. Supplementary material.
(DOCX)
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